Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.55 |
| ▸ | GSK3A | P49840 | 1/20 | 0.55 |
| ▸ | PAK4 | O96013 | 1/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.51 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 3/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | ACP1 | P24666 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801663 | 0.87 | IGF1R (0.51) | GSK3BGSK3APAK4PAK1ULK1 | |
| SCHEMBL12619761 | 0.85 | ACP1 (0.56) | GSK3BGSK3APAK4PAK1ULK1 | |
| SCHEMBL802026 | 0.84 | GSK3B (0.76) | GSK3BGSK3ANTRK1SRCAURKB | |
| SCHEMBL802833 | 0.81 | ACP1 (0.47) | GSK3BGSK3AACP1SLC2A1 | |
| SCHEMBL13055187 | 0.77 | PAK4 (0.44) | GSK3BGSK3APAK4PAK1ULK1 | |
| SCHEMBL801760 | 0.76 | IGF1R (0.47) | IGF1R | |
| SCHEMBL801861 | 0.75 | GSK3A (0.50) | GSK3BGSK3AACP1SLC2A1 | |
| SCHEMBL802386 | 0.75 | IGF1R (0.50) | IGF1R | |
| SCHEMBL802725 | 0.75 | IGF1R (0.46) | ULK1IGF1R | |
| SCHEMBL12430696 | 0.73 | ULK1 (0.65) | GSK3BPAK4PAK1ULK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | GSK3B 1/4885GSK3A 2/4885PAK4 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.